In a British investigator-initiated study conducted at the University of Kent, 123 elite athletes in endurance sports such as triathlon, marathon and cycling were randomized to treatment with ColdZyme® or to the control group. The results show a significantly shorter duration of common colds and milder common cold symptoms in upper respiratory tract infections when using ColdZyme compared to non-treated athletes.
An online survey, in which 104 ColdZyme users and 86 users of other over-the-counter products in the common cold category were evaluated, revealed that sore throat, irritated throat and feeling ill are the common cold symptoms best treated with ColdZyme, which gives the product a unique profile on the market. Among ColdZyme users, a clear majority (68%) were satisfied or very satisfied, and 88% intend to buy ColdZyme again within the next 12 months.
Post-marketing study IPSOS Q4 2019
ColdZyme was most commonly used when feeling the first symptoms of a common cold, and about one in three (32%) say that they have less frequent common colds since starting to use ColdZyme. More than half of those who use ColdZyme regularly claim that ColdZyme both relieves the symptoms and shortens the common cold.
Post Marketing Study, GfK Q4 2017
ColdZyme was evaluated by parents of 50 children aged 4 to 17 years. According to the parents, a majority of the younger children (ages 4 to 12) had fewer days with common colds and milder symptoms, and about one third responded that ColdZyme had protected their children from catching a common cold. The majority of parents would recommend the use of ColdZyme to other parents with children. The evaluation of ColdZyme in children aged 4 to 17 shows that the use, estimated effect and side effects are in line with the results among adults.
A review of four previous user surveys summarized customers' experience of using ColdZyme before they felt a common cold had broken out. Nearly half (48%) of the participants responded that using ColdZyme preventatively resulted in fewer common colds. Among the ColdZyme users who used ColdZyme preventively, 3 out of 4 (72%) felt that their common colds were milder and with fewer number of sick days. The majority of users are satisfied with ColdZyme and the repurchase rate is high, as 92% intend to buy ColdZyme again within the next 12 months.
Multi-symptom Relief and Improvement of Quality of Life – A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold, Icelandic Medical Association conference, Jan 2019
The statistically significant results from the prospective, randomized parallel group study strongly support ColdZymes intended use of reducing the duration of colds, while also broadening its clinical benefit by showing that ColdZyme significantly reduces cold symptoms. ColdZyme alleviates sore throat, nasal congestion and headache, while improving quality of life and reducing the need for concurrent use of symptom-relieving medication for colds. A total of 267 subjects with naturally acquired colds were evaluated in the study, which was designed to investigate the ability of the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21 Quality of life scale), the Jackson score, and two other scales for sore throat, to detect beneficial effects from ColdZyme when compared with a group that was not treated with ColdZyme. All four symptom scales showed statistically significantly improved effects when using ColdZyme compared with no treatment.
COLDPREV – A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold.OJRD, 2017, 7, 125–135
COLDPREV is a double-blind, placebo-controlled study of healthy volunteers who were inoculated (infected) with a cold virus. The results from explorative analyses show a reduction of viral load, as well as a reduction in the number of days with common cold symptoms in those study subjects with common cold symptoms. Both results from the explorative analyses are statistically significant compared with placebo.
ColdZyme forms a protective barrier in the throat that deactivates five major common cold viruses, Swedish Otolaryngology Congress, Apr 2018
In 2018 the results of an in vitro study were announced showing that ColdZyme® has the ability to deactivate human coronavirus, one of the most common cold virus families. Along with the in vitro results from a study published in the fall of 2017, ColdZyme has been shown to be able to deactivate the majority of the viruses known to cause colds.
A medical device forming a protective barrier that deactivates four major common cold viruses. Virology Research Reviews, Issue 5, 2017
An in vitro study was carried out in 2017 by an independent accredited and certified laboratory. The study shows that ColdZyme is able to deactivate the majority of the most common viruses (rhinovirus, influenza virus, respiratory syncytial virus and adenovirus) that cause colds in humans. The in vitro study was based on standardized and validated methods developed to resemble the in vivo environment in the mouth and throat, where the virus attaches, invades the cells and causes the cold.
User Experience of ColdZyme Mouth Spray against Common Cold in Cold in Competitive athletes, OJRD, 8, 13-20, Apr 2018
ColdZyme can be a simple and practical method for competitive athletes to prevent or alleviate colds and thereby reduce undesired absence from training and competition.
Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff. OJRD, 7, 136–140, 2017
An observational study of preschool staff shows that the number of cold-related sick days decreased from 7.4 to 4.1 days over a 6-month period, compared with historical data for the same subjects. The difference was statistically significant.
Evaluation of ColdZyme Mouth Spray against Common Cold in Elderly Care Personnel. Open Journal of Respiratory Diseases, 7, 12–17, 2016
An observational study among elderly care personnel who used ColdZyme shows that the number of cold-related sick days decreased from 5.2 to 3.7 days over a 5-month period, compared with historical data. The difference was statistically significant. In all, 63% of those who developed a cold despite using ColdZyme experienced milder cold symptoms than during previously untreated colds.
Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report.J Med Case Rep. 2016;10(1):302
A case study of a young patient with primary immunodeficiency showed that ColdZyme reduced cold symptoms, as well as secondary microbial and fungal infections of the mouth and throat.
Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.